AsclepiX Therapeutics, LLC is organized around the creation of a disruptive platform of next generation therapies using bioinformatics and systems biology methods. The approach is to design classes of short biomimetic anti-angiogenic (anti-neovascular) and anti-lymphangiogenic peptides for ocular diseases, cancer, and transplants that are structred to stop new vessel growth and to regress diseased vessels - essentially tuurning back the clock. In ophthalmology, AXT107 has a novel mechanism of action that inhibits the activity of VEGF and activates Tie 2 with a single intravitreal agent and with fewer monthly injections than other ocular therapies. In oncology, AXT201 prolongs survival in vivo in hepatocellular carcinoma and inhibits angiogenesis and lymphangiogenesis in vivo in Triple Negative Breast Cancer, stops cancer growth and stops cancer spread. In transplant, AXT501 blocks VEGFR3, which inhibits lymphangiogenesis in vivo to minimize rejection of skin, limb, and organ transplant. Management are focused primarily on orphan diseases, diseases with high mortality and diseases having a significant treatment burden on the patient.
